Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

Zynerba Pharmaceuticals logo

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.26
$1.34
50-Day Range
$1.21
$1.39
52-Week Range
$0.25
$1.40
Volume
862,700 shs
Average Volume
515,333 shs
Market Capitalization
$70.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Remove Ads
Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Headlines

ZYNE Stock Analysis - Frequently Asked Questions

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02.

Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Cronos Group (CRON), Meta Platforms (META) and Aurora Cannabis (ACB).

Company Calendar

Last Earnings
5/15/2023
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZYNE
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
1.29

Miscellaneous

Free Float
46,905,000
Market Cap
$70.12 million
Optionable
Optionable
Beta
1.32

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ZYNE) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners